已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors

T790米 变构调节 埃罗替尼 阿法替尼 表皮生长因子受体 吉非替尼 突变体 表皮生长因子受体抑制剂 西妥昔单抗 癌症研究 化学 酪氨酸激酶 蛋白激酶结构域 激酶 药理学 生物 癌症 生物化学 受体 结直肠癌 基因 遗传学
作者
Yong Jia,Cai‐Hong Yun,Eunyoung Park,Dalia Ercan,Mari Manuia,Jose Juarez,Chunxiao Xu,Kevin Rhee,Ting Chen,Haikuo Zhang,Sangeetha S. Palakurthi,Jaebong Jang,G. Lelais,Michael DiDonato,Badry D. Bursulaya,Pierre‐Yves Michellys,Robert Epple,Thomas H. Marsilje,Matthew McNeill,Wenshuo Lu
出处
期刊:Nature [Nature Portfolio]
卷期号:534 (7605): 129-132 被引量:989
标识
DOI:10.1038/nature17960
摘要

An allosteric inhibitor, EAI045, is reported that is selective for certain drug-resistant EGFR mutants, but spares the wild-type receptor; combination therapy of EAI045 with EGFR-dimerization-blocking antibodies is effective in mouse models of lung cancer driven by mutant versions of EGFR that are resistant to all previously developed inhibitors. Currently available small-molecule inhibitors targeting epidermal growth factor receptor (EGFR) and other receptor tyrosine kinases bind the ATP site of the kinase, and therefore typically inhibit a number of 'off-target' kinases owing to the high conservation of this site. In addition, the common binding site of these drugs leads to shared susceptibility to resistance-conferring mutations in EGFR. Here, Michael Eck and colleagues describe an allosteric inhibitor, EAI045, that is selective for certain drug-resistant EGFR mutants but spares the wild-type receptor. Although EAI045 is not effective in blocking EGFR-driven cell proliferation as a single agent, it has synergistic inhibitory activity when combined with an antibody that blocks EGFR dimerization. This combination therapy is effective in mouse models of lung cancer driven by mutant versions of EGFR that are resistant to all previously developed inhibitors. The epidermal growth factor receptor (EGFR)-directed tyrosine kinase inhibitors (TKIs) gefitinib, erlotinib and afatinib are approved treatments for non-small cell lung cancers harbouring activating mutations in the EGFR kinase1,2, but resistance arises rapidly, most frequently owing to the secondary T790M mutation within the ATP site of the receptor3,4. Recently developed mutant-selective irreversible inhibitors are highly active against the T790M mutant5,6, but their efficacy can be compromised by acquired mutation of C797, the cysteine residue with which they form a key covalent bond7. All current EGFR TKIs target the ATP-site of the kinase, highlighting the need for therapeutic agents with alternative mechanisms of action. Here we describe the rational discovery of EAI045, an allosteric inhibitor that targets selected drug-resistant EGFR mutants but spares the wild-type receptor. The crystal structure shows that the compound binds an allosteric site created by the displacement of the regulatory C-helix in an inactive conformation of the kinase. The compound inhibits L858R/T790M-mutant EGFR with low-nanomolar potency in biochemical assays. However, as a single agent it is not effective in blocking EGFR-driven proliferation in cells owing to differential potency on the two subunits of the dimeric receptor, which interact in an asymmetric manner in the active state8. We observe marked synergy of EAI045 with cetuximab, an antibody therapeutic that blocks EGFR dimerization9,10, rendering the kinase uniformly susceptible to the allosteric agent. EAI045 in combination with cetuximab is effective in mouse models of lung cancer driven by EGFR(L858R/T790M) and by EGFR(L858R/T790M/C797S), a mutant that is resistant to all currently available EGFR TKIs. More generally, our findings illustrate the utility of purposefully targeting allosteric sites to obtain mutant-selective inhibitors.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
SciGPT的应助被忧郁自行车采纳,获得30
1秒前
布洛芬发布了新的文献求助10
1秒前
1秒前
1秒前
1秒前
莫欣宇完成签到 ,获得积分10
2秒前
段冰旋完成签到 ,获得积分10
4秒前
舒心安柏完成签到 ,获得积分10
4秒前
ophir完成签到,获得积分20
4秒前
6秒前
FF发布了新的文献求助10
6秒前
7秒前
sh完成签到,获得积分10
8秒前
8秒前
Esther发布了新的文献求助10
9秒前
Dan发布了新的文献求助10
10秒前
所所的应助被Wynne_Wang采纳,获得10
10秒前
唐唐发布了新的文献求助10
12秒前
标致从彤完成签到,获得积分10
12秒前
13秒前
Ray完成签到,获得积分10
16秒前
桐桐的应助被司新颖采纳,获得10
18秒前
诚心海云完成签到 ,获得积分10
19秒前
20秒前
20秒前
21秒前
我是老大的应助被科研通管家采纳,获得10
21秒前
传奇3的应助被科研通管家采纳,获得50
21秒前
888的应助被科研通管家采纳,获得30
21秒前
21秒前
Maestro_S的应助被科研通管家采纳,获得10
22秒前
22秒前
绿柏完成签到 ,获得积分10
22秒前
molihuakai的应助被科研通管家采纳,获得10
22秒前
23秒前
24秒前
张兔子完成签到 ,获得积分10
25秒前
严宇耕发布了新的文献求助10
25秒前
25秒前
alex的应助被我看看怎么个事采纳,获得10
25秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184723
求助须知:如何正确求助?哪些是违规求助? 9573702
关于积分的说明 21832740
捐赠科研通 7782090
什么是DOI,文献DOI怎么找? 3434404
关于科研通互助平台的介绍 2558528
邀请新用户注册赠送积分活动 2481054